Beilstein J. Org. Chem. 2013, 9, 2925–2933.
acetate (1, 0.1 mg).
−53 (c 0.006, CHCl3); 1H NMR 13.6 Hz, 1H, H-5), 2.66 (dd, J = 7.1, 14.4 Hz, 1H, H-4a), 2.59
(CDCl3, 500 MHz) δH 7.33 (bs, 1H, H-1), 7.23 (bs, 1H, H-15), (dd, J = 7.1, 14.4 Hz, 1H, H-4b), 2.12–2.01 (m, 4H, H-8 and
6.27 (s, 1H, H-2), 5.64 (bdt, J = 6.4, 9.3 Hz, 1H, H-5), H-9), 1.65 (d, J = 1.1 Hz, 3H, CH3-14), 1.69 (s, 3H, CH3-12),
5.15 (d, J = 9.3 Hz, 1H, H-6), 5.07 (brt, J = 6.9 Hz, 1H, H-10), 1.60 (s, 3H, CH3-13); 13C NMR (CDCl3, 125 MHz) δC 142.9
2.73 (dd, J = 6.7, 14.5 Hz, 1H, H-4a), 2.63 (dd, J = 6.0, 14.5 (C-1), 140.3 (C-15), 139.5 (C-7), 131.8 (C-11), 127.0 (C-3),
Hz, 1H, H-4b), 2.15–1.95 (overlapping, m, 4H, H-8, H-9), 124.0 (C-10), 120.9 (C-6), 111.7 (C-2), 68.5 (C-5), 39.6 (C-8),
1.72 (s, 3H, H-14), 1.67 (s, 3H, H-12), 1.59 (s, 3H, H-13); 33.3 (C-4), 26.4 (C-9), 25.7 (C-12), 17.8 (C-13), 16.7 (C-14);
13C NMR (CDCl3, 125 MHz) δC 142.7 (C-1), 141.5 (C-7), (+)-LRESIMS m/z: 257 [M + Na]+.
140.1 (C-15), 132.0 (C-11), 123.9 (C-10), 123.7 (C-6), 120.2
(C-3), 111.8 (C-2), 70.7 (C-5), 32.5 (C-8), 30.7 (C-4), 26.5 (±)-(Z)-1-(furan-3-yl)-4,8-dimethylnona-3,7-dien-2-ol (7b):
(C-9), 25.7 (C-12), 23.3 (C-14), 17.6 (C-13); (+)-HRESIMS Colorless glass; 1H NMR (CDCl3, 500 MHz) δH 7.37 (s, 1H,
m/z: [M + Na]+ calcd. for C17H24NaO3, 299.1618; found, H-1), 7.29 (s, 1H, H-15), 6.32 (s, 1H, H-2), 5.24 (d, J = 8.8 Hz,
299.1624.
1H, H-6), 5.07 (brt, J = 5.4 Hz, 1H, H-10), 4.48 (q, J = 6.7, 13.6
Hz, 1H, H-5), 2.65 (dd, J = 7.2, 14.4 Hz, 1H, H-4a), 2.58 (dd, J
Procedure for Wittig rearrangement of 3-furylmethyl ether = 7.2, 14.4 Hz, 1H, H-4b), 2.12–2.01 (m, 4H, H-8 and H-9),
(6) [21]: To a solution of (E/Z)-3-furylmethyl ether (6, 200 mg) 1.74 (d, J = 1.1 Hz, 3H, CH3-14), 1.69 (s, 3H, CH3-12), 1.60 (s,
in THF (10 mL) was added dropwise first LDA (3.64 mL, 3H, CH3-13); 13C NMR (CDCl3, 125 MHz) δC 142.9 (C-1),
10 wt % suspension in hexane) followed by t-BuLi (2.5 mL, 140.3 (C-15), 139.5 (C-7), 132.6 (C-11), 128.0 (C-3), 124.0
1.6 M in hexanes;) at −78 °C under Ar. After stirring for 1 h (C-10), 121.1 (C-6), 111.7 (C-2), 68.1 (C-5), 33.2 (C-8), 32.5
(the reaction mixture was allowed to warm to 0 °C), the reac- (C-4), 26.6 (C-9), 25.8 (C-12), 23.5 (C-14), 17.8 (C-13); (+)-
tion mixture was quenched with sat. aq NH4Cl solution and the HRESIMS m/z: [M + Na]+ calcd for C15H22NaO2, 257.1512;
solvent was removed under vacuum. The residue was extracted found, 257.1515.
with pentane/Et2O (1:1, v/v). The extract was washed with
brine and dried over Na2SO4. Evaporation of the solvent gave a Procedure for acetylation of (±)-(Z)-1-(furan-3-yl)-4,8-
residue, which was chromatographed on silica gel (5.0 g, dimethylnona-3,7-dien-2-ol (7b): A portion of 7b (8.4 mg)
hexanes/AcOEt 95:5) to afford the desired product (E/Z ratio was dissolved in dry pyridine (0.5 mL) and cooled in an ice
~3:1) as a mixture of enantiomers (83 mg, 39% yield). The E- bath. After the addition of acetic acid anhydride (1.5 mL) the
and Z-isomers of 5-hydroxydendrolasin were then separated by mixture brought to rt and stirred for 1.5 hours. Toluene
NP HPLC (hexanes/EtOAc 90:10, flow rate 2 mL/min, refrac- (0.5 mL) was added and the resulting azeotrope was evaporated
tive index detection, Waters μPorasilTM column 10 μm, under reduced pressure to give (±)-(6Z)-dendrolasin-5-acetate
300 × 7.8 mm) to give the individual 6E ((7a); 25.2 mg; tR = (1) (6.4 mg); 1H and 13C NMR data (CDCl3, 500 MHz) are
50.0 min) and 6Z ((7b); 8.4 mg; tR = 40.0 min) isomers. Analyt- identical to those of 1. (+)-LRESIMS m/z 299 [M + Na]+.
ical enantioselective HPLC separation of the Z-isomer of
5-hydroxydendrolasin (7b) was performed on an Agilent 1200 Procedure for acetylation of the (+) isomer of 7b: A portion
series liquid chromatography system (isocratic conditions of 2% of the (+) isomer of 7b (1.3 mg) was acetylated using the same
isopropanol in n-hexane, flow rate of 0.5 mL min−1) equipped procedure as for 7b to obtain (−)-(6Z)-dendrolasin-5-acetate (1,
with UV (214 nm) and ALP (Advanced Laser Polarimeter, 0.9 mg); Colorless glass; [α]D −8.7 (c 0.06, CHCl3); 1H and
PDR-Chiral Inc.) detectors and a Chiralpak AD column 13C NMR data (CDCl3, 500 MHz) are the same as those of the
(250 × 4.6 mm, Daicel Chemical Industries Ltd.). The prepara- 1. (+)-LRESIMS m/z: 299 [M + Na]+.
tive enantioselective HPLC purification of 7b used isocratic
conditions (1.5% isopropanol in n-hexane, flow rate of 10 mL Procedure for acetylation of the (−)-isomer of 7b: A portion
min−1) with UV detection at 220 nm and a Chiralpak AD of the (−)-isomer of 7b (1.3 mg) was acetylated using the same
column (250 × 20 mm, Daicel Chemical Industries Ltd.) to give procedure as for 7b to obtain (+)-(6Z)-dendrolasin-5-acetate (1,
the (+)-enantiomer (2.7 mg); (−)-enantiomer (2.6 mg). The 1.1 mg); Colorless glass; [α]D +12.9 (c 0.07, CHCl3); 1H and
retention times were: 29.5 min ((+)-enantiomer); 32.1 min ((−)- 13C NMR (CDCl3, 500 MHz) are identical to those of 1. (+)-
enantiomer).
LRESIMS m/z: 299 [M + Na]+.
(±)-(E)-1-(furan-3-yl)-4,8-dimethylnona-3,7-dien-2-ol (7a) Procedure for preparation of (R)- and (S)-MPA esters of
[21]: Colorless glass; 1H NMR (CDCl3, 500 MHz) δH 7.37 (s, racemic (6Z)-5-hydroxydendrolasin (7b): (±)-(6Z)-5-
1H, H-1), 7.29 (s, 1H, H-15), 6.32 (s, 1H, H-2), 5.24 (d, J = 8.5 Hydroxydendrolasin (2.0 mg) was dissolved in dry DCM
Hz, 1H, H-6), 5.07 (brt, J = 7.1 Hz, 1H, H-10), 4.51 (q, J = 7.1, (0.2 mL) to which (R)-methoxyphenylacetic acid (MPA)
2931